prof. Bart Vandekerckhove (MD, PhD)

CRIG group leader
Bart Vandekerckhove

Director of GMP Unit Cell therapy (CellGENTherapies), Cord blood Bank and Hematopoietic Stem cell Bank, UZ Gent
Professor Department of Clinical Chemistry, microbiology and immunology


Research focus

  • Generation of effective CAR/TCR transgenic T cells
  • Enabling phase I trials with cell and gene therapy medicinal products
  • Neoepitope discovery in human cancer
  • RNA vaccines and ATMPs

Research team

Key publications

  • ​​​​​​​Single-cell profiling identifies a novel human polyclonal unconventional T cell lineage. J Exp Med. 2023 Jun 5;220(6):e20220942. doi: 10.1084/jem.20220942. Epub 2023 Mar 20. PMID: 36939517; PMCID: PMC10037106.
  • Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials. Cytotherapy. 2022 Feb;24(2):213-222. doi: 10.1016/j.jcyt.2021.08.005. Epub 2021 Oct 22. PMID: 34696961.
  • The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation. Blood. 2020 Jul 16;136(3):288-298. doi: 10.1182/blood.2020005204. PMID: 32350509.
  • Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly. Int J Mol Sci. 2020 Jan 30;21(3):883. doi: 10.3390/ijms21030883. PMID: 32019116; PMCID: PMC7037261.
  • Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol Med. 2020 Feb 7;12(2):e11223. doi: 10.15252/emmm.201911223. Epub 2020 Jan 8. PMID: 31912630; PMCID: PMC7709889.
  • The human fetal thymus generates invariant effector γδ T cells. J Exp Med. 2020 Mar 2;217(3):jem.20190580. doi: 0.1084/jem.20190580. PMID: 31816633; PMCID: PMC7062527.

Contact & links